165 related articles for article (PubMed ID: 37720495)
1. Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis.
Gasparri ML; Albasini S; Truffi M; Favilla K; Tagliaferri B; Piccotti F; Bossi D; Armatura G; Calcinotto A; Chiappa C; Combi F; Curcio A; Della Valle A; Ferrari G; Folli S; Ghilli M; Listorti C; Mancini S; Marinello P; Mele S; Pertusati A; Roncella M; Rossi L; Rovera F; Segattini S; Sgarella A; Tognali D; Corsi F
Ther Adv Med Oncol; 2023; 15():17588359231193732. PubMed ID: 37720495
[TBL] [Abstract][Full Text] [Related]
2. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy.
Şahin AB; Cubukcu E; Ocak B; Deligonul A; Oyucu Orhan S; Tolunay S; Gokgoz MS; Cetintas S; Yarbas G; Senol K; Goktug MR; Yanasma ZB; Hasanzade U; Evrensel T
Sci Rep; 2021 Jul; 11(1):14662. PubMed ID: 34282214
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of neutrophil-to-lymphocyte-ratio in neoadjuvant-treated patients with breast cancer.
von Au A; Shencoru S; Uhlmann L; Mayer L; Michel L; Wallwiener M; Hennigs A; Deutsch T; Riedel F; Heil J; Golatta M; Schneeweiss A; Schütz F; Domschke C
Arch Gynecol Obstet; 2023 Apr; 307(4):1105-1113. PubMed ID: 35980458
[TBL] [Abstract][Full Text] [Related]
5. The predictive value of neutrophil-to-lymphocyte ratio for overall survival and pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy.
Gao S; Tang W; Zuo B; Mulvihill L; Yu J; Yu Y
Front Oncol; 2022; 12():1065606. PubMed ID: 36727046
[TBL] [Abstract][Full Text] [Related]
6. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer.
Vila J; Mittendorf EA; Farante G; Bassett RL; Veronesi P; Galimberti V; Peradze N; Stauder MC; Chavez-MacGregor M; Litton JF; Huo L; Kuerer HM; Hunt KK; Caudle AS
Ann Surg Oncol; 2016 Oct; 23(11):3501-3509. PubMed ID: 27216742
[TBL] [Abstract][Full Text] [Related]
7. Association of immune inflammatory biomarkers with pathological complete response and clinical prognosis in young breast cancer patients undergoing neoadjuvant chemotherapy.
Li F; Wang Y; Dou H; Chen X; Wang J; Xiao M
Front Oncol; 2024; 14():1349021. PubMed ID: 38380360
[TBL] [Abstract][Full Text] [Related]
8. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
9. Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy.
Barron AU; Hoskin TL; Day CN; Hwang ES; Kuerer HM; Boughey JC
JAMA Surg; 2018 Dec; 153(12):1120-1126. PubMed ID: 30193375
[TBL] [Abstract][Full Text] [Related]
10. Axillary Downstaging in Occult Primary Breast Cancer After Neoadjuvant Chemotherapy.
Botty Van den Bruele A; Lavery J; Plitas G; Pilewskie ML
Ann Surg Oncol; 2021 Feb; 28(2):968-974. PubMed ID: 32813202
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
12. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Nomogram for Prediction of Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer.
Kim JY; Park HS; Kim S; Ryu J; Park S; Kim SI
Medicine (Baltimore); 2015 Oct; 94(43):e1720. PubMed ID: 26512562
[TBL] [Abstract][Full Text] [Related]
14. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
[TBL] [Abstract][Full Text] [Related]
15. Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer.
Ladak F; Chua N; Lesniak D; Ghosh S; Wiebe E; Yakimetz W; Rajaee N; Olson D; Peiris L
Can J Surg; 2022; 65(1):E89-E96. PubMed ID: 35135785
[TBL] [Abstract][Full Text] [Related]
16. A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer.
Kantor O; Sipsy LM; Yao K; James TA
Ann Surg Oncol; 2018 May; 25(5):1304-1311. PubMed ID: 29368152
[TBL] [Abstract][Full Text] [Related]
17. Laboratory indicators predict axillary nodal pathologic complete response after neoadjuvant therapy in breast cancer.
Chen P; Zhao T; Bi Z; Zhang ZP; Xie L; Liu YB; Song XG; Song XR; Wang CJ; Wang YS
Future Oncol; 2021 Jul; 17(19):2449-2460. PubMed ID: 33878939
[TBL] [Abstract][Full Text] [Related]
18. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
[TBL] [Abstract][Full Text] [Related]
19. Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy.
Zhu J; Li J; Fan Z; Wang H; Zhang J; Yin Y; Fu P; Geng C; Jin F; Jiang Z; Liu Z
Ann Transl Med; 2020 Aug; 8(16):992. PubMed ID: 32953792
[TBL] [Abstract][Full Text] [Related]
20. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
